Stem
cell therapy for cardiac failure has astounded the medical profession
and resulted in the immediate implementation of clinical trials
to fast-track regulation and implementation. The Regenecell treatment
protocol for cardiac failure has been used successfully since
2007 and is the same procedure that is to be followed in future
FDA-approved clinical trials. Patients with extremely poor ejection
fractions have responded well enough to return to a normal lifestyle
with minimal medication needs.
Below is an article commissioned by Regenecell Pty Ltd,
to supplement the current anecdotal data on stem cell therapy.
For additional information, contact: info@regenecell.com
Stem cell therapy and cardiac failure
Stem cell therapy is the latest tool in regenerative cardiac medical
therapy. Its potential for use in cardiovascular disease has only
recently been recognized in clinical trials. A randomized study
was conducted in 20 patients to deploy stem cells as an adjuvant
to conventional revascularization therapy in patients with congestive
heart failure. 1
Injections of adult stem cells into damaged heart tissue significantly
improved heart function in patients with severe congestive heart
failure, according to results of the first prospective randomized
trial of the experimental therapy. 4
The results were astounding in that this study proved that in
the early stages of recovery the stem cell transplant group fared
the same as the surgical group, but at one month post-treatment,
the gap widened to show that the stem cell treated group started
doing better and the surgical group stagnated. This carried through
for the rest of the study period and by six months the stem cell
treated group had improved an average of 46% as compared to only
35% in the surgically treated group.1 The head researcher
for this study stated their findings provide the first convincing
evidence that transplantation of adult stem cells that promote
growth of blood vessels and heart muscle can be a viable treatment
for congestive heart failure.4
It is now becoming widely accepted that stem cells can repair
heart tissue and now the structure of clinical trials seems to
be focused on how many and what type of cells to use and not whether
this works or not. During the writing of this article the author
noted 6 FDA-approved clinical trials currently recruiting patients.
2
In 2008, Mayo Clinic investigators have demonstrated that stem
cells can be used to regenerate heart tissue to treat dilated
cardiomyopathy, one of the causes of cardiac failure. Interesting
to note here is that the responses also seemed to start after
one month as in the first study mentioned above.3
We see that by using the correct stem cells augmented by RegAmp
in a minimally invasive procedure we achieve the same results,
which according to our track record, is, on average a 40% improvement
over baseline after three months. These are the best results available
today and are borne out by their similarity to results that have
been attained in animal and human studies in FDA-approved clinical
trials. We have not experienced any adverse events in any of our
patients during this safe and effective procedure, which can be
performed at any one of the Regenecell clinics worldwide.
References:
1. Patel A N et al. Surgical treatment for congestive
heart failure with autologous adult stem cell transplantation:
A prospective randomized study. J Thor & Card Surgery. Vol 130,
Issue 6, Pages 1631-1638 (December 2005).
2. http://www.clinicaltrials.gov/
3. http://www.physorg.com/news140352761.html
4. http://www.mirm.pitt.edu/news/article.asp?qEmpID=64
